Novo Reports CagriSema Weight Loss and Function Results
Plainsboro, New Jersey, USA, and Bagsværd, Denmark, November 15, 2026 Novo Nordisk has announced two new post hoc analyses...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Plainsboro, New Jersey, USA, and Bagsværd, Denmark, November 15, 2026 Novo Nordisk has announced two new post hoc analyses...
Washington, D.C., USA, November 14, 2026 Novo Nordisk has announced positive primary results from its Phase 3 REDEFINE 9...
Boulder, Colorado, USA, November 15, 2026 Ambrosia Biosciences has announced new nonclinical findings for two investigational oral small-molecule drug...
Indianapolis, Indiana, United States, November 11, 2026 Eli Lilly and Company has announced detailed 52-week Phase 3b clinical results...
SYDNEY, Australia — September 25, 2026 Aptar Pharma announced a new three-year research collaboration with Macquarie University supported by...
Bagsværd, Denmark, September 21, 2026 Novo Nordisk has announced topline results from two Phase 3 trials evaluating CagriSema, an...
Taipei, Taiwan, September 11, 2026 Avance Clinical has received the Australia-Taiwan Business Excellence Award from the Australia New Zealand...
Jerusalem, Israel, September 8, 2026 Scinai Immunotherapeutics has announced a strategic refocusing of its research and development portfolio following...
Chicago, Illinois, USA, September 8, 2026 Orphalan has initiated the global Phase 3 TRADITiONAL clinical trial evaluating an investigational...
Daejeon, South Korea, September 2, 2026 Alteogen Inc. has entered into an option and license agreement with Novartis to...
